|
Market Closed -
Nasdaq
16:00:00 2026-10-20 EDT
|
5-day change | 1st Jan Change | ||
| 514.65 USD | +2.53% |
|
+6.07% | +13.52% |
| 10-15 | Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653 | MT |
| 10-09 | Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children | MT |
Business description: Vertex Pharmaceuticals Incorporated
Net sales are distributed geographically as follows: the United States (62.9%), Europe (28.8%) and other (8.3%).
Number of employees: 6,400
Sales by Activity: Vertex Pharmaceuticals Incorporated
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Pharmaceuticals | 7.57B | 8.93B | 9.87B | 11.02B | 12B |
Geographical breakdown of sales: Vertex Pharmaceuticals Incorporated
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 5.29B | 5.7B | 6.04B | 6.68B | 7.55B |
Europe | 1.97B | 2.71B | 3.11B | 3.45B | 3.46B |
Other | 313M | 526M | 720M | 881M | 992M |
Executive Committee: Vertex Pharmaceuticals Incorporated
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 2020-03-31 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 2019-04-09 |
Sean Daughtry
CTO | Chief Tech/Sci/R&D Officer | - | 2024-02-29 |
Edward Atkinson
CTO | Chief Tech/Sci/R&D Officer | 60 | 2023-08-28 |
Mark Bunnage
CTO | Chief Tech/Sci/R&D Officer | 57 | 2021-06-30 |
Composition of the Board of Directors: Vertex Pharmaceuticals Incorporated
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 66 | 1997-12-31 |
Jeffrey Leiden
CHM | Chairman | 70 | 2012-04-30 |
Sangeeta Bhatia
BRD | Director/Board Member | 57 | 2015-06-17 |
Alan Garber
BRD | Director/Board Member | 70 | 2017-06-07 |
| Director/Board Member | 53 | 2020-02-29 | |
Lloyd Carney
BRD | Director/Board Member | 64 | 2019-02-20 |
Diana McKenzie
BRD | Director/Board Member | 61 | 2020-06-02 |
Michel Lagarde
BRD | Director/Board Member | 52 | 2023-10-04 |
Nancy Thornberry
BRD | Director/Board Member | 69 | 2023-12-04 |
| Director/Board Member | 51 | 2024-05-14 |
Company details: Vertex Pharmaceuticals Incorporated
Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.53% | +6.07% | +22.80% | +42.22% | 130B | |
| +3.49% | +10.04% | +58.68% | +119.56% | 1,144B | |
| +2.19% | +4.32% | +33.88% | +69.52% | 625B | |
| +2.26% | +5.37% | +24.57% | +97.69% | 511B | |
| +2.58% | +8.37% | +38.71% | +63.14% | 377B | |
| +3.25% | +4.45% | +71.80% | +44.44% | 366B | |
| +1.85% | +6.04% | +21.47% | +49.17% | 291B | |
| +1.76% | +6.07% | +0.43% | +20.98% | 262B | |
| +3.29% | +6.32% | +44.71% | +57.43% | 237B | |
| +2.25% | +5.81% | +27.13% | +101.17% | 194B | |
| Average | +2.09% | +4.38% | +34.42% | +66.53% | 413.84B | |
| Weighted average by Cap. | +1.46% | +4.73% | +40.35% | +79.46% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VRTX Stock
- Company Vertex Pharmaceuticals Incorporated
Select your edition
All financial news and data tailored to specific country editions
